Drug intelligence / Profile preview

GC3106

Development stage: Phase 3
Lead developer: 绿十字
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GC3106 is a **quadrivalent, cell-culture-based influenza vaccine** developed to prevent human influenza infection. It employs an immunostimulant approach, meaning it stimulates the immune system to provoke an immune response against influenza viruses. The vaccine is indicated for the prophylaxis (prevention) of influenza and has been studied in randomized, double-blind, active-controlled Phase III trials to assess its immunogenicity (ability to provoke an immune response) and safety in humans. GC3106, also referenced as GC-3106A, was developed by Green Cross Co., Ltd.[3]

Brand names: GC3106GC-3106GC 3106
Other names: GC3106GC-3106GC 3106GC-3106AGC3106AGC 3106A

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on GC3106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC3106.

Explore the full profile